Hypertrophic cardiomyopathy echocardiography: Difference between revisions

Jump to navigation Jump to search
Line 8: Line 8:


==Frequency of Hypertrophy==
==Frequency of Hypertrophy==
While LVH is often present, not all carriers with HCM demonstrate [[left ventricular hypertrophy]].
While LVH is usually present, not all carriers with HCM demonstrate [[left ventricular hypertrophy]].  [[LVH]] may be time dependent and may appear late, particularly in patients with a mutation in the myosin-binding protein C gene.  Patients generally present later in life and in general, have a better prognosis than beta myosin heavy chain or cardiac troponin T mutations.  Up to 60% of patients at age 50 years have no  evidence of [[LVH]].  LVH may appear later in life in these patients. Because of this, a normal EKG and a normal ECHO at maturity does not exclude the presence of an HCM mutation <ref>Erdmann J, Raible J, Maki-Abadi J et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001;38:322–30.</ref>.


==Diagnostic Fefatures==
==Diagnostic Fefatures==

Revision as of 23:09, 21 August 2011

Hypertrophic Cardiomyopathy Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hypertrophic Cardiomyopathy from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hypertrophic cardiomyopathy echocardiography On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hypertrophic cardiomyopathy echocardiography

CDC on Hypertrophic cardiomyopathy echocardiography

Hypertrophic cardiomyopathy echocardiography in the news

Blogs on Hypertrophic cardiomyopathy echocardiography

Directions to Hospitals Treating Hypertrophic cardiomyopathy

Risk calculators and risk factors for Hypertrophic cardiomyopathy echocardiography

Editors-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Echocardiography is the imaging modality of choice in the diagnosis of hypertrophic cardiomyopathy. Classically there is a small left ventricular cavity with hypertrophy out of proportion to any underlying condition that would cause LVH. The hypertrophy is often asymmetric.

Frequency of Hypertrophy

While LVH is usually present, not all carriers with HCM demonstrate left ventricular hypertrophy. LVH may be time dependent and may appear late, particularly in patients with a mutation in the myosin-binding protein C gene. Patients generally present later in life and in general, have a better prognosis than beta myosin heavy chain or cardiac troponin T mutations. Up to 60% of patients at age 50 years have no evidence of LVH. LVH may appear later in life in these patients. Because of this, a normal EKG and a normal ECHO at maturity does not exclude the presence of an HCM mutation [1].

Diagnostic Fefatures

  • Left ventricular hypertrophy (LVH) most often in an asymmetric distribution,
  • Thickening of the left ventricular wall in the absence of cavitary dilation and the presence of hyperdynamic activity (in fact there may be systolic cavity obliteration or near obliteration)
  • Absnece of any other cause of left ventricular hypertrophy such as aortic stenosis or hypertension

Left Ventricular Wall Thickness

  • The traditional definition requires a wall thickness > 15 mm.
  • Borderline wall thicknesses of 13-14 mm must be distinguished from extreme variants of athletes heart
  • There are some genetic variants that yield a normal wall thickness [2][3][4][5][6].
  • Among children < 13 years of age, LVH is often absent.

References

  1. Erdmann J, Raible J, Maki-Abadi J et al. Spectrum of clinical phenotypes and gene variants in cardiac myosin-binding protein C mutation carriers with hypertrophic cardiomyopathy. J Am Coll Cardiol 2001;38:322–30.
  2. Niimura H, Bachinski LL, Sangwatanaroj S et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:1248–57.
  3. Maron BJ, Niimura H, Casey SA et al. Development of left ventricular hypertrophy in adults in hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001;38:315–21.
  4. Charron P, Dubourg O, Desnos M et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in a genotyped adult population. Circulation 1997; 96:214–9.
  5. Charron P, Dubourg O, Desnos M et al. Diagnostic value of electrocardiography and echocardiography for familial hypertrophic cardiomyopathy in genotyped children. Eur Heart J 1998;19:1377–82.
  6. Panza JA, Maron BJ. Relation of electrocardiographic abnormalities to evolving left ventricular hypertrophy in hypertrophic cardiomyopathy during childhood. Am J Cardiol 1989;63:1258–65.